Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression

Mark W. Ball, Stephania M. Bezerra, Alcides Chaux, Sheila F. Faraj, Nilda Gonzalez-Roibon, Enrico Munari, Rajni Sharma, Trinity Bivalacqua, George J. Netto, Arthur Burnett

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate insulin-like growth factor-1 receptor (IGF1R) expression in penile cancer and its association with oncologic outcomes. Methods: Tissue microarrays were constructed from 53 patients treated at our institution. Expression of IGF1R was evaluated using a Her2-like scoring system. Overexpression was defined as 1+ or greater membranous staining. Association of IGF1R expression with pathologic features was assessed with comparative statistics, and association with local recurrence, progression to nodal or distance metastases, or death was assessed with Kaplan-Meier survival analysis and Cox proportional hazard regression models. Results: Overall, IGF1R overexpression was seen in 33 (62%) cases. With a median follow-up of 27.8 months, IGF1R overexpression was associated with inferior progression-free survival (PFS) (P = .003). In a multivariable model controlling for grade, T stage, perineural invasion, and lymphovascular invasion, IGF1R expression was independently associated with disease progression (hazard ratio 2.3, 95% confidence interval 1.1-5.1, P = .03. Comparing patients without IGF1R overexpression to those with overexpression, 5-year PFS was 94.1% vs 45.8%. Conclusion: IGF1R overexpression was associated with inferior PFS in penile cancer. Drugs that target IGF1R and downstream messengers may have a therapeutic benefit in patients that exhibit IGF1R overexpression.

Original languageEnglish (US)
JournalUrology
DOIs
StateAccepted/In press - Dec 12 2015

Fingerprint

Penile Neoplasms
Somatomedin Receptors
Disease-Free Survival
Kaplan-Meier Estimate
Survival Analysis
Proportional Hazards Models
Disease Progression

ASJC Scopus subject areas

  • Urology

Cite this

Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression. / Ball, Mark W.; Bezerra, Stephania M.; Chaux, Alcides; Faraj, Sheila F.; Gonzalez-Roibon, Nilda; Munari, Enrico; Sharma, Rajni; Bivalacqua, Trinity; Netto, George J.; Burnett, Arthur.

In: Urology, 12.12.2015.

Research output: Contribution to journalArticle

Ball, Mark W. ; Bezerra, Stephania M. ; Chaux, Alcides ; Faraj, Sheila F. ; Gonzalez-Roibon, Nilda ; Munari, Enrico ; Sharma, Rajni ; Bivalacqua, Trinity ; Netto, George J. ; Burnett, Arthur. / Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression. In: Urology. 2015.
@article{7c0e7824f8464966b72f7183df84c084,
title = "Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression",
abstract = "Objective: To evaluate insulin-like growth factor-1 receptor (IGF1R) expression in penile cancer and its association with oncologic outcomes. Methods: Tissue microarrays were constructed from 53 patients treated at our institution. Expression of IGF1R was evaluated using a Her2-like scoring system. Overexpression was defined as 1+ or greater membranous staining. Association of IGF1R expression with pathologic features was assessed with comparative statistics, and association with local recurrence, progression to nodal or distance metastases, or death was assessed with Kaplan-Meier survival analysis and Cox proportional hazard regression models. Results: Overall, IGF1R overexpression was seen in 33 (62{\%}) cases. With a median follow-up of 27.8 months, IGF1R overexpression was associated with inferior progression-free survival (PFS) (P = .003). In a multivariable model controlling for grade, T stage, perineural invasion, and lymphovascular invasion, IGF1R expression was independently associated with disease progression (hazard ratio 2.3, 95{\%} confidence interval 1.1-5.1, P = .03. Comparing patients without IGF1R overexpression to those with overexpression, 5-year PFS was 94.1{\%} vs 45.8{\%}. Conclusion: IGF1R overexpression was associated with inferior PFS in penile cancer. Drugs that target IGF1R and downstream messengers may have a therapeutic benefit in patients that exhibit IGF1R overexpression.",
author = "Ball, {Mark W.} and Bezerra, {Stephania M.} and Alcides Chaux and Faraj, {Sheila F.} and Nilda Gonzalez-Roibon and Enrico Munari and Rajni Sharma and Trinity Bivalacqua and Netto, {George J.} and Arthur Burnett",
year = "2015",
month = "12",
day = "12",
doi = "10.1016/j.urology.2016.02.006",
language = "English (US)",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression

AU - Ball, Mark W.

AU - Bezerra, Stephania M.

AU - Chaux, Alcides

AU - Faraj, Sheila F.

AU - Gonzalez-Roibon, Nilda

AU - Munari, Enrico

AU - Sharma, Rajni

AU - Bivalacqua, Trinity

AU - Netto, George J.

AU - Burnett, Arthur

PY - 2015/12/12

Y1 - 2015/12/12

N2 - Objective: To evaluate insulin-like growth factor-1 receptor (IGF1R) expression in penile cancer and its association with oncologic outcomes. Methods: Tissue microarrays were constructed from 53 patients treated at our institution. Expression of IGF1R was evaluated using a Her2-like scoring system. Overexpression was defined as 1+ or greater membranous staining. Association of IGF1R expression with pathologic features was assessed with comparative statistics, and association with local recurrence, progression to nodal or distance metastases, or death was assessed with Kaplan-Meier survival analysis and Cox proportional hazard regression models. Results: Overall, IGF1R overexpression was seen in 33 (62%) cases. With a median follow-up of 27.8 months, IGF1R overexpression was associated with inferior progression-free survival (PFS) (P = .003). In a multivariable model controlling for grade, T stage, perineural invasion, and lymphovascular invasion, IGF1R expression was independently associated with disease progression (hazard ratio 2.3, 95% confidence interval 1.1-5.1, P = .03. Comparing patients without IGF1R overexpression to those with overexpression, 5-year PFS was 94.1% vs 45.8%. Conclusion: IGF1R overexpression was associated with inferior PFS in penile cancer. Drugs that target IGF1R and downstream messengers may have a therapeutic benefit in patients that exhibit IGF1R overexpression.

AB - Objective: To evaluate insulin-like growth factor-1 receptor (IGF1R) expression in penile cancer and its association with oncologic outcomes. Methods: Tissue microarrays were constructed from 53 patients treated at our institution. Expression of IGF1R was evaluated using a Her2-like scoring system. Overexpression was defined as 1+ or greater membranous staining. Association of IGF1R expression with pathologic features was assessed with comparative statistics, and association with local recurrence, progression to nodal or distance metastases, or death was assessed with Kaplan-Meier survival analysis and Cox proportional hazard regression models. Results: Overall, IGF1R overexpression was seen in 33 (62%) cases. With a median follow-up of 27.8 months, IGF1R overexpression was associated with inferior progression-free survival (PFS) (P = .003). In a multivariable model controlling for grade, T stage, perineural invasion, and lymphovascular invasion, IGF1R expression was independently associated with disease progression (hazard ratio 2.3, 95% confidence interval 1.1-5.1, P = .03. Comparing patients without IGF1R overexpression to those with overexpression, 5-year PFS was 94.1% vs 45.8%. Conclusion: IGF1R overexpression was associated with inferior PFS in penile cancer. Drugs that target IGF1R and downstream messengers may have a therapeutic benefit in patients that exhibit IGF1R overexpression.

UR - http://www.scopus.com/inward/record.url?scp=84963959747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963959747&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2016.02.006

DO - 10.1016/j.urology.2016.02.006

M3 - Article

C2 - 26905033

AN - SCOPUS:84963959747

JO - Urology

JF - Urology

SN - 0090-4295

ER -